[Skip to Content]
[Skip to Content Landing]
Views 14,402
Citations 0
Original Investigation
June 18, 2019

Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes

Author Affiliations
  • 1Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
  • 2Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
  • 3School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
  • 4Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada
  • 5Substance Use Program Team, The Ottawa Hospital, Ottawa, Ontario, Canada
  • 6Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, Canada
JAMA. 2019;322(2):145-152. doi:10.1001/jama.2019.8734
Key Points

Question  Is there an association between prenatal cannabis exposure and maternal, perinatal, and neonatal outcomes?

Findings  In this retrospective cohort study that included 661 617 pregnancies and 9427 reported cannabis users, the rate of preterm birth among reported cannabis users was 12% vs 6% in nonusers, a statistically significant difference.

Meaning  Reported cannabis use in pregnancy was associated with significant increases in the rate of preterm birth following adjustment for confounding.

Abstract

Importance  Recent evidence suggests that cannabis use during pregnancy is increasing, although population-based data about perinatal outcomes following in utero exposure remain limited.

Objective  To assess whether there are associations between self-reported prenatal cannabis use and adverse maternal and perinatal outcomes.

Design, Setting, and Participants  Population-based retrospective cohort study covering live births and stillbirths among women aged 15 years and older in Ontario, Canada, between April 2012 and December 2017.

Exposures  Self-reported cannabis exposure in pregnancy was ascertained through routine perinatal care.

Main Outcomes and Measures  The primary outcome was preterm birth before 37 weeks’ gestation. Indicators were defined for birth occurring at 34 to 36 6/7 weeks’ gestation (late preterm), 32 to 33 6/7 weeks’ gestation, 28 to 31 6/7 weeks’ gestation, and less than 28 weeks’ gestation (very preterm birth). Ten secondary outcomes were examined including small for gestational age, placental abruption, transfer to neonatal intensive care, and 5-minute Apgar score. Coarsened exact matching techniques and Poisson regression models were used to estimate the risk difference (RD) and relative risk (RR) of outcomes associated with cannabis exposure and control for confounding.

Results  In a cohort of 661 617 women, the mean gestational age was 39.3 weeks and 51% of infants were male. Mothers had a mean age of 30.4 years and 9427 (1.4%) reported cannabis use during pregnancy. Imbalance in measured maternal obstetrical and sociodemographic characteristics between reported cannabis users and nonusers was attenuated using matching, yielding a sample of 5639 reported users and 92 873 nonusers. The crude rate of preterm birth less than 37 weeks’ gestation was 6.1% among women who did not report cannabis use and 12.0% among those reporting use in the unmatched cohort (RD, 5.88% [95% CI, 5.22%-6.54%]). In the matched cohort, reported cannabis exposure was significantly associated with an RD of 2.98% (95% CI, 2.63%-3.34%) and an RR of 1.41 (95% CI, 1.36-1.47) for preterm birth. Compared with no reported use, cannabis exposure was significantly associated with greater frequency of small for gestational age (third percentile, 6.1% vs 4.0%; RR, 1.53 [95% CI, 1.45-1.61]), placental abruption (1.6% vs 0.9%; RR, 1.72 [95% CI, 1.54-1.92]), transfer to neonatal intensive care (19.3% vs 13.8%; RR, 1.40 [95% CI, 1.36-1.44]), and 5-minute Apgar score less than 4 (1.1% vs 0.9%; RR, 1.28 [95% CI, 1.13-1.45]).

Conclusions and Relevance  Among pregnant women in Ontario, Canada, reported cannabis use was significantly associated with an increased risk of preterm birth. Findings may be limited by residual confounding.

×